LUND and LINKÖPING,
Sweden, May
22, 2018 /PRNewswire/ -- Immunovia AB today announced that
Linköping University Hospital is to participate in PanFAM-1, the
largest ever prospective study looking at early diagnosis in
high-risk individuals with Familial Pancreatic Cancer (FPC).
Designed to validate Immunovia ́s innovative blood test, IMMray™
PanCan-d, the study will analyze more than thousand individuals
over three years across sites in Sweden, the US and Europe already offering FPC screening
programs. The aim is to improve the outcome for the cancer patients
and to prove the overall healthcare benefits of testing persons
with heredity for pancreatic cancer. Parallel to this Immunovia is
also running a study for another newly identified high risk group,
new onset diabetics over 50 years of age.
"We know from worldwide experience that early surgical
intervention is essential in treating pancreatic cancer," says
Associate Professor Thomas
Gasslander, Dept of Surgery, Linköping University Hospital.
"Members of families with heredity for pancreatic cancer have an
increased risk to develop pancreatic cancer, but so far we lack
accurate, non-invasive early diagnostic tools. A test such as
IMMray™ PanCan-d could be of great value in the surveillance of
this group and therefore we are pleased to join the PanFAM-1 study
along with other colleagues in Sweden, USA,
UK and Spain."
"The entry of Linköping University Hospital to PanFAM-1 marks a
major step forward as we aim to establish a national program for
early detection of pancreatic cancer among major risk groups here
in Sweden," commented Mats Grahn, CEO, Immunovia. "It also strengthens
the study's overall reach across Europe and the US. We are on schedule to
present interim results in 2019."
The other PanFAM-1 partners to date are: Mount Sinai, New York; Knight Cancer
Institute at Oregon Health and Sciences University, Portland, OR; The University of Pittsburgh Medical Center
Pittsburgh, PA; The
Massachusetts General Hospital, Boston,
MA; NYU School of Medicine, New York; The
University of Liverpool, UK; Ramon
y Cajal Institute for Health Research Madrid, Spain; University Hospital of
Santiago de Compostela,
Spain, Clínica Universidad de Navarra, Spain and Sahlgrenska University Hospital,
Gothenburg, Sweden. Advanced
discussions over potential participation continue with several
other European and US centers running high risk surveillance
programs.
For more information, please contact:
Mats Grahn
Chief Executive Officer, CEO, Immunovia
Tel.: +46-70-5320230
Email: mats.grahn@immunovia.com
About Immunovia
Immunovia AB was founded in 2007 by investigators from the
Department of Immunotechnology at Lund University and CREATE Health, the Center
for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to
decipher the wealth of information in blood and translate it into
clinically useful tools to diagnose complex diseases such as
cancer, earlier and more accurately than previously possible.
Immunovia´s core technology platform, IMMray™, is based on antibody
biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early
diagnosis of pancreatic cancer. In the beginning of 2016, the
company started a program focused on autoimmune diseases
diagnosis, prognosis and therapy monitoring. The first test from
this program, IMMray™ SLE-d, is a biomarker signature derived for
differential diagnosis of lupus, now undergoing evaluation and
validation. (Source: www.immunovia.com)
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
About Pancreatic Cancer
Pancreatic Cancer is one of the most deadly and difficult to
detect cancers, as the signs and symptoms are diffuse and similar
to other diseases. There are more than 40,000 deaths and over
50,000 new cases diagnosed each year in the U.S. alone, and the
five-year survival rate for pancreatic cancer is currently 5-8 %.
It is predicted to become the second leading cause of cancer death
by 2020. However, because resection is more successful in stage
I/II, early diagnosis can significantly improve pancreatic cancer
patients' 5-year survival rates from 5-8 % to up to 49%.
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/immunovia-ab/r/linkoping-university-hospital-second-swedish-site-in-largest-ever-prospective-multicenter-clinical-s,c2527845
The following files are available for download:
http://mb.cision.com/Main/13121/2527845/846053.pdf
|
Press Release
Immunovia Linköping PanFAM-1
|
View original
content:http://www.prnewswire.com/news-releases/linkoping-university-hospital-second-swedish-site-in-largest-ever-prospective-multicenter-clinical-study-for-early-detection-of-pancreatic-cancer-300652759.html
SOURCE Immunovia AB